Survey of chronic pain in Chile – prevalence and treatment, impact

Por um escritor misterioso

Last updated 05 julho 2024

Survey of chronic pain in Chile – prevalence and treatment, impact

Background and aims The prevalence of chronic non-cancer pain has not been specifically reported in Chile. Methods In order to assess its prevalence and impact, we designed a tool based on previously published survey studies. We analyzed a sample of 784 subjects to determine the prevalence of chronic non-cancer pain, with a maximum variability of 50%, a confidence interval (CI) of 95%, and an estimation error of 3.5%. Finally, a cross-sectional cell phone survey was conducted on a nationally representative probability sample of 865 subjects of over 18 years, in November 2013. The prevalence of chronic non-cancer pain was estimated by using expansion factors according to national projections by age group and gender, from the Chilean National Institute of Statistics for the year 2010. Results The estimated prevalence of chronic non-cancer pain was 32.1% (95% CI: 26.5–36.0). The respondents with chronic non-cancer pain presented the following results: 65.7% had moderate pain, and 20.8%, severe pain; 65.6% had somatic pain, 31.7% neuropathic pain, and 2.7% visceral pain. Approximately 70% reported they were receiving some kind of pharmacological treatment with certain frequency. In 64.9%, medication was prescribed by a physician. The prevalence of sick leave in workers was 30.22%, with a median duration of 14 days (interquartile range: 14; range: 1–60). Conclusions Chronic non-oncological pain occurs in 32% of Chilean adults. These figures provide the first measurement of chronic non-cancer pain in the Chilean population. Implications Chronic non-oncological pain impact as a public health problem is revealed, given the high prevalence found, and the elevated private and social costs involved.

Chronic Pain & Management

PDF) Survey of chronic pain in Chile - Prevalence and treatment, impact on mood, daily activities and quality of life

Neuropathic pain: epidemiology, risks and prevention

Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In U.S.

Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia - Jan de Beur - 2023 - Journal of Internal Medicine - Wiley Online Library

Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023

Effects of therapeutic alliance on clinical outcomes in patients with symptomatic knee osteoarthritis undergoing an exercise program: A randomized clinical trial protocol - Medwave